Acting Attorney General Todd Blanche signed an order Thursday reclassifying FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act - the most consequential federal drug policy shift in more than fifty years. The move does not legalize cannabis. Recreational cannabis stays Schedule I. But for licensed medical operators, the financial and regulatory implications are immediate and real, and a new administrative hearing process launching June 29 will determine whether all marijuana follows.
What the Order Actually Changes - and What It Doesn't Touch
The scope matters more than the headline. This rescheduling is not blanket. It covers two categories: FDA-approved marijuana products and state-licensed medical marijuana. Everything outside those categories - adult-use cannabis sold through licensed recreational dispensaries, unlicensed products, unregistered patients - remains classified Schedule I. Forty states operate licensed medical programs that now carry explicit federal recognition of accepted medical use for the first time. That is not a small thing. But recreational operators in adult-use states should read carefully before updating their financial projections.
What the order does, in concrete terms:
- Formally recognizes accepted medical use for FDA-approved marijuana products and state-licensed medical cannabis
- Gives state-licensed medical marijuana operators access to standard federal tax deductions, previously blocked by IRS code 280E
- Eases barriers to federally sanctioned research on cannabis
- Creates an expedited DEA registration pathway for licensed medical operators
- Launches a June 29 administrative hearing process to consider full rescheduling of all marijuana
What it does not do:
- Does not legalize cannabis at the federal level
- Does not reschedule adult-use or recreational cannabis
- Does not affect sentences of people incarcerated on cannabis charges
- Does not change federal workplace drug testing policy
- Does not permit interstate cannabis commerce
- Does not expunge records or decriminalize possession
Cannabis has been locked at Schedule I since the early 1970s - same category as heroin, defined under the Controlled Substances Act as having no accepted medical use and high abuse potential. Schedule III carries a very different meaning: accepted medical use, moderate to low dependence potential. That definitional shift, applied to state-licensed medical programs across forty states, is the mechanism through which 280E exposure changes for qualifying operators.
The 280E Question - Who Sees Relief and Who Waits
For plant-touching cannabis businesses, 280E has been the most punishing structural cost in the industry. Because Schedule I and Schedule II substances are treated identically under that provision, operators have been unable to deduct ordinary business expenses - rent, payroll, utilities, cost of goods beyond direct production - from their federal taxable income. Effective tax rates for many cannabis operators have run dramatically higher than comparable retailers in other sectors as a result. That changes now for state-licensed medical operators.
Here's the catch, though: recreational-only operators in adult-use states are in a genuinely ambiguous position until the June 29 hearing process resolves. And in states where a single licensed store holds both medical and adult-use endorsements - Washington state's hybrid licensing structure is one example - the operational and accounting implications are not yet clear. Operators in those situations will need guidance from tax counsel before adjusting how they file.
Mark Lewis, President of Specialty Payments at cannabis payments platform Lüt, offered a useful corrective to the more optimistic read of Thursday's announcement. "The biggest misconception is that rescheduling suddenly normalizes the business of cannabis," Lewis said. "The financial system doesn't move at the speed of a headline. Banks, card networks and regulators are still reacting to risk, and when risk is unclear, their default is to pull back, not lean in." His point stands. The SAFE Banking Act remains unpassed. Cannabis businesses - medical or otherwise - will continue operating without reliable access to conventional banking and card processing until federal legislation addresses those structural barriers directly. Rescheduling reduces the symbolic risk profile. It does not rewrite the compliance calculus that keeps most financial institutions on the sideline.
The Equity Gap That Tax Relief Doesn't Close
Financial relief for licensed operators is real. It is also incomplete - and advocates with a longer memory are saying so directly. Sasha Nutgent, VP of Cannabis Retail at Housing Works Cannabis Co., one of the country's most prominent social equity operators, welcomed the shift but was measured about what it means in practice. "Rescheduling doesn't undo the deeper harm caused by decades of the War on Drugs," Nutgent said. "The same communities hit hardest are still working to gain fair access to this industry, and that can't be overlooked and won't change overnight. Cannabis should never have been classified the way it was in the first place. This is a step forward, but there's still a lot of work to do to get it right."
That tension runs through the entire policy moment. The operators most likely to benefit quickly from 280E relief are established multi-state operators with diversified medical footprints - companies like Trulieve, whose CEO Kim Rivers was present at the Oval Office for Trump's December executive order signing, or publicly traded operators with the legal and accounting infrastructure to act fast. Social equity licensees, many of whom are still fighting for capitalization, retail space, and basic operational stability, are less positioned to absorb and act on the change immediately. That asymmetry is not incidental. It is a structural feature of how cannabis reform has moved at every stage.
What Operators Should Watch Between Now and June 29
Thursday's action is formally a two-track process. Track one - the immediate rescheduling of FDA-approved marijuana products and state-licensed medical cannabis - is done. Track two, covering all marijuana including adult-use, moves into an expedited administrative hearing process beginning June 29, with set deadlines. Cannabis analyst Pablo Zuanic had previously outlined a faster path - a final order dropping directly into the Federal Register with a 30-day challenge window - and a slower path involving two to three months of structured hearings. The June 29 timeline confirms the administration chose the more deliberate route for the broader question.
Legal challenges are expected. More than twenty Republican senators signed a letter last year urging the administration to maintain existing restrictions. A pending interlocutory appeal related to allegations of agency bias during the earlier DEA review process remains unresolved. Ricardo Baca, founder and CEO of public affairs firm Grasslands and former cannabis editor of The Denver Post, called the moment historic while cautioning against reading too much into it. "While most Americans still don't understand what this reclassification means - because it's not full legalization or even the descheduling of cannabis so that it's treated like alcohol - that doesn't mean today's move isn't still historic," Baca said. "Once cannabis is moved to Schedule III, we will have witnessed the single-biggest U.S. drug policy shift of our lifetimes."
Fair enough. For licensed medical operators, the 280E exposure that has suppressed margins for years is now addressed - partially and contingently, but addressed. For recreational operators, payments infrastructure, interstate commerce, and banking access: none of it moves Thursday. The date that matters next is June 29.
